Skip to main navigation
Skip to content
  • Careers
  • Contact
Pyxis Oncology Logo
  • About
    • Overview
    • Leadership
    • Partners
  • Analyst Coverage
  • Our Approach
    • ADC Landscape
    • I/O Landscape
  • Portfolio
    • A NOVEL PIPELINE
    • ADCS
    • OUR TARGET CATALOG
  • Investors
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Proxy and Annual Meeting
Pyxis Oncology Logo
  • About
    • Overview
    • Leadership
    • Partners
  • Analyst Coverage
  • Our Approach
    • ADC Landscape
    • I/O Landscape
  • Portfolio
    • A NOVEL PIPELINE
    • ADCS
    • OUR TARGET CATALOG
  • Investors
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Proxy and Annual Meeting
  • Careers
  • Contact

News releases

Dec 23, 2022
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PDF Version
Dec 01, 2022
Pyxis Oncology Announces FDA Clearance of Two IND Applications
PDF Version
Nov 01, 2022
Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update
PDF Version
Sep 30, 2022
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PDF Version
Aug 15, 2022
Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update
PDF Version
Jul 12, 2022
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PDF Version
Jun 28, 2022
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference
PDF Version
May 19, 2022
Pyxis Oncology Announces Presentations at Upcoming Investor Conferences
PDF Version
May 13, 2022
Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
PDF Version
Apr 27, 2022
Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference
PDF Version

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 14

150 Cambridgepark Drive
8th Floor, Suite 2
Cambridge, MA 02140
(617) 453-3596 | info@pyxisoncology.com

Pyxis Oncology
Twitter > Linkedin-in >
Copyright © 2023 Pyxis Oncology   
|   Privacy Policy